Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 1

Status

Recruiting 2Active not recruiting 1

Sponsor Class

NIH 3

Study Type

Interventional 3

Sponsor

Cancer Type

Gynecologic 3Breast 3Thoracic 2Gastrointestinal 2Plasma cell 1NET 1Endocrine 1

Conditions

Melanoma 7Ovarian Neoplasms 6Pancreatic Neoplasms 4Carcinoma, Renal Cell 4Carcinoma, Non-Small-Cell Lung 4Breast Neoplasms 4Urogenital Neoplasms 3Stomach Neoplasms 3Neoplasm Metastasis 3Leukemia, Myeloid, Acute 3Gastrointestinal Neoplasms 3Triple Negative Breast Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Skin Neoplasms 2Rectal Neoplasms 2Multiple Myeloma 2Colorectal Neoplasms 2Colonic Neoplasms 2Carcinoma, Squamous Cell 2Urinary Bladder Neoplasms 1Thyroid Carcinoma, Anaplastic 1Sarcoma 1Recurrence 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pleural Effusion, Malignant 1Osteosarcoma 1Neuroendocrine Tumors 1Neuroblastoma 1Myelodysplastic Syndromes 1

Interventions

pembrolizumab 3fludarabine 3aldesleukin 3Cyclophosphamide 3cabozantinib 2Specimen Handling 2Nivolumab 2Magnetic Resonance Spectroscopy 2Ipilimumab 2CTLA-4 Antigen 2olaparib 1gallium 68 PSMA-11 1enfortumab vedotin 1darolutamide 1Therapeutics 1Radiosurgery 1Radiation Dose Hypofractionation 1Pluvicto 1Mitomycin 1Lutetium-177 1Lutetium 1Loperamide 1Geriatric Assessment 1Gemcitabine 1Fulvestrant 1Fluorouracil 1Fecal Microbiota Transplantation 1Exercise 1Continuous Positive Airway Pressure 1Cisplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Urogenital Neoplasms × aldesleukin × 90 days × Clear all
NCT01174121 2026-06-05

Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer

National Institutes of Health Clinical Center (CC)

Phase 2 Recruiting
332 enrolled
BreastGastrointestinalGynecologic

Breast Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Urogenital Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms

NCT03412877 2026-05-29

Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer

National Institutes of Health Clinical Center (CC)

Phase 2 Recruiting
285 enrolled
BreastEndocrineGynecologicNETPlasma cellThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Multiple Myeloma, Ovarian Neoplasms, Urogenital Neoplasms, Neuroendocrine Tumors

NCT06253520 2026-05-08

Autologous T-cells Genetically Engineered to Express Receptors Reactive Against KRAS Mutations in Conjunction With a Vaccine Directed Against These Antigens in Participants With Metastatic Cancer

National Institutes of Health Clinical Center (CC)

Phase 1 Active not recruiting
210 enrolled
BreastGastrointestinalGynecologicThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Gastrointestinal Neoplasms, Ovarian Neoplasms, Urogenital Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡